(May 11, 2020, 2:26 PM EDT) -- PHILADELPHIA — Generic drug manufacturer Apotex Corp. on May 7 agreed to pay a $24.1 million penalty and to enter into a deferred prosecution agreement with the U.S. Justice Department for conspiring with other general drug makers to increase the price of the heart drug pravastatin from May 2013 to December 2015 (United States v. Apotex Corp., No. 20-cr-169, E.D. Pa.)....